Drug intelligence / Profile preview

prednisolone + amoxicillin + clavulanate

Development stage
Unknown
Lead developer
University of Chicago
Modality
Small Molecules
Administration
Oral
01

Overview

This investigational combination therapy, studied by the University of Chicago, consists of the systemic corticosteroid prednisolone and the antibiotic combination amoxicillin/clavulanate. It is being evaluated in a Phase 4 clinical trial (titled 'Steroids and Antibiotics for Childhood OSAS') for the treatment of mild obstructive sleep apnea syndrome (OSAS) in children aged 18 months to 12 years. The therapeutic rationale is to reduce the size of hypertrophic tonsils and adenoids by addressing both inflammation and potential chronic bacterial infection within the lymphoid tissues. By shrinking these tissues, the treatment aims to alleviate airway obstruction and improve sleep symptoms, potentially serving as a non-surgical alternative or adjunct to adenotonsillectomy, which is the standard first-line treatment for pediatric OSA.

Brand names
Augmentin
Other names
amoxicillin + clavulanate-University of Chicago-obstructive sleep apnea syndromeSteroids and Antibiotics for Childhood OSAS
02

Targets

GR (Glucocorticoid receptor)PBP (Penicillin-binding protein family)β-lactamase

Beyond the preview

Go deeper on prednisolone + amoxicillin + clavulanate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on prednisolone + amoxicillin + clavulanate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call